VJOncology Podcast

HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. It was associated with a poor prognosis until the approval of trastuzumab, a monoclonal antibody targeting HER2. Since then, the therapeutic landscape for patients with HER2-positive tumors has changed dramatically, with the introduction of other monoclonal antibodies such as pertuzumab, tyrosine kinase inhibitors includin...

For patients with lung cancer, surgical resection is a treatment option and perioperative management is imperative to improve surgical outcomes. Patients undergoing surgery may face a decline in quality of life, especially those who have co-morbidities or are older. Prehabilitation aims to prepare patients mentally and physically before surgery with exercise, nutrition and stress reduction. Whilst...

Gastrointestinal (GI) cancer remains one of the leading cause of global cancer mortality. The current standard for diagnosing GI cancers via biopsy is costly and invasive, as well as lacking in reliability. As such, these methods are not used for screening and the majority of GI cancers are diagnosed in the advanced stages of cancer progression, when curative surgery is inadequate and patients mus...

Cellular immunotherapy approaches have proven to be highly effective in the treatment of patients with hematological malignancies over recent years. In contrast, the efficacy of cellular immunotherapy in solid tumors has been restricted due to a limited array of tumor-specific antigens to differentiate cancer cells from normal cells.  In this podcast, we spoke with three leading experts in cellula...

The San Antonio Breast Cancer Symposium 2021 featured exciting developments in early and advanced breast cancer, basic science, and translational research. In this podcast, we had the opportunity to hear from Lisa A. Carey (UNC Lineberger, Chapel Hill, NC) and Aleix Prat (Hospital Clínic Barcelona, Barcelona, Spain) who discuss advances in breast cancer care and management, including highlights fr...

The success of immunotherapy in the treatment of solid tumors has created hope for its potential in breast cancer. The San Antonio Breast Cancer Symposium 2021 showcased an array of updates in breast cancer care and management, including updates on pivotal trials evaluating the use of immunotherapy in breast cancer. In this podcast, we hear from leading experts, Kevin Kalinsky (Emory University, A...

The Lung Cancer Sessions from VJOncology aim to provide interesting perspectives from leading experts on the big topics in lung cancer research. In this podcast, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, chairs a lively discussion on the latest advances and standard clinical practices in EGFR-mutated NSCLC, including EGFR testing, options for first-line treatment, and developme...

Liquid biopsy is an exciting field, with many promising advances in recent years. In this podcast, we cover a range of possible uses of liquid biopsy throughout all stages of patient care, from early diagnosis and screening to post-treatment monitoring. We also discuss some of the key challenges that need to be overcome, and think about the future of liquid biopsy research.   We are joined by four...

The European Society for Medical Oncology (ESMO) 2021 Congress saw many exciting clinical trials presented from across the field of oncology, some of which are paving the way for new standards of care for patients. Among the biggest readouts for the field of prostate cancer were the STAMPEDE (NCT00268476), PEACE-1 (NCT01957436), and ARCHES (NCT02677896) studies. In this podcast, we are joined by R...

VJOncology has assembled a group of leading genitourinary cancer experts to examine and discuss the exciting developments in bladder cancer presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting. Listen to this insightful roundtable discussion featuring Laurence Albiges, Gustave Roussy Institute, Villejuif, France, and Enrique Grande, MD Anderson Cancer Center Madrid, Ma...

Following the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, VJOncology brought together a group of leading lung cancer experts to offer their perspectives on the latest research advances presented at the meeting and how they could impact lung cancer care in the future. In this exclusive post-ASCO podcast, Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, is j...

At the virtual 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, important advances and potentially practice-changing trial data were presented in a range of gastrointestinal (GI) malignancies such as esophageal, gastric and colorectal cancer. VJOncology has assembled an esteemed panel of leading GI experts to discuss the latest exciting developments, what these advances could...

VJOncology has assembled a panel of world-renowned skin cancer experts to examine and discuss the exciting advances in skin cancer presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. In this exclusive podcast, James Larkin, MD, PhD, Royal Marsden Hospital, London, UK, is joined by Rodabe Amaria, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ana...

Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been the first-line treatment options for many years. To address the limitations of platinum-based chemotherapeutics, additional therapeutics have become available in more recent years for first- and second-line use. Specifically, for patients who are ci...

This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and discuss the latest findings in oncology. In this podcast, Pedro Barata, MD, MSc Tulane University School of Medicine, New Orleans, LA, discusses highlights from the meeting. He focuses on the results from four Phase III trials assessing various therapies for the treat...

During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.   This post-ASCO GU...

VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Can...

Various immunotherapies including checkpoint inhibitors have emerged as effective treatment options for patients with non-small cell lung cancer (NSCLC). Immune checkpoints proteins such as PD-1, PD-L1 and CTLA-4 have become promising targets, as they have an immunosuppressive function and are overexpressed in certain cancers. Several checkpoint inhibitors have already received FDA approval includ...

Whilst advances in diagnostic procedures, radiotherapies, cisplatin-based chemotherapy, and surgery have meant that testicular cancer is curable in around 95% of cases, the side effects of radiotherapy and chemotherapy can significantly impact quality-of-life (QoL) outcomes for patients treated for testicular cancer in both the short and long term. Currently, much research is investigating how nov...

The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting took place virtually this year and leading experts came together to present on the most recent developments in GI cancer. In this podcast, Paolo Manca, MD, Istituto Nazionale dei Tumori Milano, Milano, Italy, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Dan Aderka, MD, Sheba Medical Ce...

Metastatic breast cancer is breast cancer that has spread to other regions of the body, most commonly the liver, brain, bones, or lungs. Cancer cells migrate from the original tumor site in the breast and travel to other regions in the body through the bloodstream or lymphatic system. Although significant developments have been made in the treatment options available for patients with metastatic b...

Healthcare systems around the world differ in financial and political situations. Therefore, it is vital to implement a global outlook of breast cancer care that focuses on applying access to high-quality practices, especially in low- and middle-income countries, where breast cancer remains a public health crisis.    During this podcast, Andre Ilbawi, MD, of the World Health Organization (WHO), Ca...

Surgery is an effective treatment for non-metastatic melanoma, however, advanced melanoma demands additional intervention, such as chemotherapy or immunotherapy. The development of immunotherapies for melanoma has significantly improved outcomes for patients with metastatic cancer. Several immunotherapies for metastatic melanoma have already received FDA approval, including nivolumab and ipilimuma...

Prostate-specific membrane antigen (PSMA) is overexpressed in more than 80% of  prostate cancer  tumors, making it a promising diagnostic and therapeutic target. Given the highly limited expression of PSMA outside of the prostate, precision approaches that specifically target PSMA have been of substantial interest in the field. PSMA-targeted radionuclide therapy combines a PSMA ligand with a radio...

Breast cancer is the most common type of cancer in women. Although most cases of early-stage non-metastatic disease are curable with surgery, effective treatments for later-stage and metastatic disease remain an unmet need. Several immunotherapies have received FDA approval for the treatment of breast cancer, including pembrolizumab, atezolizumab and trastuzumab deruxtecan. In this podcast, Rebecc...